Helix BioMedix Announces U.S. Patent Issuance for Cosmetic Compositions Containing...

Helix BioMedix Announces U.S. Patent Issuance for Cosmetic Compositions Containing Short Bioactive Peptides

Patent Covers Peptides Included in More Than Twenty Commercially
Available Products
BOTHELL, Wash.--(Business Wire)--
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive
peptides, today announced that it has been issued U.S. Patent number
7,354,903 by the United States Patent and Trademark Office.

The patent covers more than eighty proprietary peptides for use in
cosmetic and skin care applications and products. There are currently
over 20 marketed products using peptides protected under the patent
including such cosmeceutical brands as Fusion Beauty, Smashbox,
Isomers, and B. Kamins. Numerous additional product roll outs are
planned for later this year.

"The issuance of this patent is a key step in the protection of
the intellectual property associated with our proprietary peptides,
which is of critical importance to the company," stated R. Stephen
Beatty, President and CEO of Helix BioMedix, Inc. "While our primary
focus is dermatological therapeutic development, this represents our
first issued patent specifically targeting cosmetic and skin care
applications, which is the direct result of our efforts to diversify
our sequences as well as their bioactivities and application. We
currently have additional patent applications filed targeting the skin
care market, which we hope will continue the expansion of the
company's proprietary library of bioactive peptides over the next
several years."

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with over 50
patents supporting an extensive library of peptides that are diverse
in structure, sequence, and bioactivity. We are a leader in creating
novel, first in class, lipohexapeptide drug candidates, with an
initial focus on the large topical anti-infective market including
indications such as acne, rosacea, MRSA and fungal infections. We are
also focusing on the design of peptides for the consumer market where,
to date, we have entered into partnerships with six companies engaged
in supplying high-quality ingredients to the cosmetic and
cosmeceutical sectors. Our core competencies include peptide design,
synthesis and characterization together with assay development,
screening, tissue culture and microbiology, leveraged through
relationships with contract research organizations and peptide
manufacturers. We have the capability to take peptide-based products
from a theoretical concept to a safe and efficacious finished product.

More information about the company and its proprietary peptides
may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include statements regarding activities, events or
developments that the company expects, believes or anticipates may
occur in the future, including statements related to its potential
growth, product development and commercialization and revenue. A
number of factors could cause actual results to differ from those
indicated in the forward-looking statements, including the company's
ability to successfully raise additional capital, enter into revenue
generating license agreements, continue its research and development
efforts, including pre-clinical and clinical studies, continue
developing marketable peptide-based products and general economic
conditions. Additional assumptions, risks and uncertainties are
described in detail in the company's reports and other filings with
the Securities and Exchange Commission. Such filings are available on
the company's website or at www.sec.gov. Readers are cautioned that
such forward-looking statements are not guarantees of future
performance and actual results or developments may differ materially
from those set forth in the forward-looking statements. The company
undertakes no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances.

Helix BioMedix
R. Stephen Beatty, 425-402-8400
President and CEO
sbeatty@helixbiomedix.com
or
Investor Contact
Shelton Group Investor Relations
Ryan Bright, 972-239-5119 X 159
rbright@sheltongroup.com

Copyright Business Wire 2008